Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects

Exclusion Criteria

• •1\. Subjects who have clinically significant abnormalities in clinical laboratory tests.
• •2\. Subjects with clinical significance of abnormal ECG, chest x-ray.
• •3\. Subjects with history of hypertension.
• •4\. Subject who are or had been suffering from malignant neoplasm; subject who are or had been suffering from inflammatory bowel disease.
• •5\. Subjects who have an active infection within 2 months prior to screening, including acute and chronic infections as well as localized infections.
• •6\. Subjects who have active tuberculosis.
• •7\. Subjects who have been exposed to TB within 3 months prior to screening.
• •8\. Subjects whose T-cell test for tuberculosis infection (T-SPOT.TB) results are positive.
• •9\. Subjects who are positive for HBsAg on the hepatitis B half test.
• •10\. Subjects who have had a major injury or undergone previous surgical procedures or fracture within 4 weeks prior to enrollment.
• •11\. Subjects who have taken any prescription medication within 28 days prior to screening.
• •12\. Subjects who participate in another drug clinical trial within 3 months prior to enrollment.
• •13\. Subjects who suffered an acute illness from the screening period until study drug administration.
• •14\. Subjects who have received Mepolizumab (or its biosimilar) within 6 months (or within 5 half-lives of the drug, whichever is longer) prior to screening.
• •15\. Subjects who have received live vaccination during the study period within 12 weeks prior to study dosing.
• •16\. Subjects who are suspected or confirmed to be allergic (allergic to multiple medications or foods).
• •17\. Subjects who smoked more than 5 cigarettes per day in the 3 months prior to screening.
• •18\. Subjects who have taken any alcohol-containing product within 24h prior to study dosing.
• •19\. Subjects who have donated blood or lost a significant amount of blood (\> 450 mL) within 3 months prior to study drug administration.
• •20\. Subjects with a positive urine drug screening.
• •21\. Subject who is deemed unsuitable for enrollment by the investigator.